MedTrace Logo

Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis

NCT05897294 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-11-21

No results posted yet for this study

Summary

Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks. Duration of treatment may be extended on a case-by-case basis depending on drug availability and after discussion with the Sponsor.

Conditions

  • Invasive Pulmonary Aspergillosis
  • Allergic Bronchopulmonary Aspergillosis
  • Chronic Pulmonary Aspergillosis
  • Aspergillus Tracheobronchitis
  • Anastomotic Infection
  • Pulmonary Fungal Infection

Interventions

DRUG

Voriconazole Inhalation Powder

dry powder inhalation of voriconazole

Sponsors & Collaborators

  • TFF Pharmaceuticals, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05897294 on ClinicalTrials.gov